Therapeutic Target Details
| Target ID: | T11 |
| Target Name: | Hepatic lipase |
| Synonyms: | HTGL; Hepatic triacylglycerol lipase; Lipase member C; Lysophospholipase; Phospholipase A1; Hepatic lipase; 3.1.1.3; 3.1.1.5; 3.1.1.32 |
| GENE: | LIPC |
| Action: | |
| Class: | Hydrolase |
| UniProtKB ID: | P11150 |
| Entry Name: | LIPC_HUMAN |
| Related Drugs: | |
| Mechanism: | |
| Reference (PMIDs): |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria |
|---|
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B175943 | CHEMBL106126 | Small molecule | 266.34 | C14H22N2O3 | Details | ||
| B217770 | CHEMBL131588 | Small molecule | 426.85 | C18H14ClF3N4OS | NEUTRAL | Details | |
| B218451 | CHEMBL133897 | Small molecule | 312.32 | C17H16N2O4 | NEUTRAL | Details | |
| B218493 | CHEMBL339297 | Small molecule | 367.41 | C20H21N3O4 | NEUTRAL | Details | |
| B218499 | CHEMBL131051 | Small molecule | 408.4 | C18H15F3N4O2S | NEUTRAL | Details | |
| B293438 | CHEMBL175247 | Small molecule | ORLISTAT | 495.75 | C29H53NO5 | NEUTRAL | Details |
| B1560474 | CHEMBL2381069 | Small molecule | 345.48 | C20H24FNOS | NEUTRAL | Details | |
| B1607681 | CHEMBL3093302 | Small molecule | 369.31 | C18H15F4NO3 | ACID | Details | |
| B1607771 | CHEMBL3093391 | Small molecule | 331.33 | C16H20F3NO3 | ACID | Details | |
| B1607772 | CHEMBL3093392 | Small molecule | 366.34 | C18H17F3N2O3 | ACID | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00063 | 15126514 | J Clin Endocrinol Metab | The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. | Details |
| A00111 | 18364377 | J Clin Endocrinol Metab | The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects. | Details |